Showing results (31-40 of 696) with videos related to
Sort By:
Pageof 70
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 21, 2012
Impact of glycaemic control on the effect of direct renin inhibition in the AVOID studyFrederik Persson, Julia B Lewis, Edmund J Lewis, et al.Kidney International|July 18, 2017
Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathyJulie Galsgaard, Frederik Persson, Tine Willum Hansen, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2011
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathyFrederik Persson, Julia B Lewis, Edmund J Lewis, et al.Journal of Diabetes and Its Complications|October 23, 2016
Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatmentEmilie Hein Zobel, Bernt Johan von Scholten, Morten Lindhardt, et al.Diabetes Care|August 10, 2010
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathyFrederik Persson, Julia B Lewis, Edmund J Lewis, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|August 10, 2011
Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudyFrederik Persson, Julia B Lewis, Edmund J Lewis, et al.Journal of Hypertension|June 8, 2013
Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?Frederik Persson, Xifeng Lu, Peter Rossing, et al.Diabetes, Obesity & Metabolism|January 22, 2019
Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatmentEmilie H Zobel, Bernt J von Scholten, Bryan Goldman, et al.Diabetes, Obesity & Metabolism|March 5, 2023
Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetesElisabeth B Stougaard, Peter Rossing, Dorte Vistisen, et al.Diabetes|November 30, 2006
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudyFrederik Persson, Peter Rossing, Peter Hovind, et al.Pageof 70